<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-2">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: <br />improved haematological parameters with eltrombopag
			</div>


			<div class="content-container">
				
				<table class="red">
					<tr>
						<th colspan="2" style="text-align:center">Response rate: 40% (17/43) – patients who achieved a response in<br />≥1 cell lineage at 12/16 weeks<sup>1</sup></th>
					</tr>
					<tr class="odd" style="font-weight:bold">
						<td>Response criteria, n (%)</td>
						<td></td>
					</tr>
					<tr>
						<td>
							Unilineage<br />
							Multilineage<br />
							Bilineage<br />
							Trilineage

						</td>
						<td>
							13 (76)<br />
							4 (24)<br />
							3 (18)<br />
							1 (6)
						</td>
					</tr>
					<tr class="odd" style="font-weight:bold">
						<td>Response by lineage, n (%)</td>
						<td>
							
						</td>
					</tr>

					<tr>
						<td>Platelets<br />
							Erythrocytes<br />
							Neutrophils
						</td>
						<td>11 (65)s<br />
							3 (18)s<br />
							8 (47
						</td>
					</tr>

				</table>

			</div>

		</div>


		<div class="information-overlay overlay">
			
			<header>Phase II study in refractory aplastic anaemia: improved haematological parameters with eltrombopag</header>
			
			<ul>
				<li><span>Primary endpoints at Week 12 were defined according to the haematological responses to, and the safety and tolerability of, eltrombopag<sup>2</sup></span></li>
				<li><span>Patients who met the 12-week response criteria received eltrombopag for an additional 4 weeks to ensure the stability of the response, and then had the option to continue treatment for as long as the response was maintained<sup>2</sup></span></li>
				<li><span>Haematological responses in additional cell lineages were assessed in patients who demonstrated a response and in those who participated in the extension study<sup>2</sup></span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ClinicalOverview-v2.5.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/OlnesM-2012-NEJM-v367p11.pdf"><span>Olnes M <i>et al. N Engl J Med</i> 2012;367:11</span></li>
			</ol>

		</div>

	</div>
</div>